ASH 2022 | Luspatercept for the treatment of patients with lower-risk MDS and ESA failure
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a study looking at potential strategies to optimize luspatercept treatment in patients with myelodysplastic syndromes (MDS) following erythropoiesis-stimulating agent (ESA) failure. In the study, combining an ESA such as darbepoetin with luspatercept induced responses, including in patients who had previously failed both ESAs and luspatercept. The combination had minimal side effects and so could be considered for those with no clinical trial options or for those who have failed luspatercept therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Intellia: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Lixte: Patents & Royalties: LB-100; Nemucore: Membership on an entity’s Board of Directors or advisory committees.
